Utility of levetiracetam in patients with subarachnoid hemorrhage
Related Experiment Video
Updated: Jun 19, 2026

Pre-Chiasmatic, Single Injection of Autologous Blood to Induce Experimental Subarachnoid Hemorrhage in a Rat Model
Published on: June 18, 2021
1Department of Medicine (Neurology), Duke University Medical Center, Durham, NC, USA.
Purpose:
To determine the utility and tolerability of levetiracetam (LEV) compared to phenytoin (PHT) in preventing clinical seizures in patients with subarachnoid hemorrhage (SAH).
Methods:
Utility and tolerability of PHT and LEV in patients with SAH were determined by the occurrence of breakthrough clinical seizures or adverse events necessitating a change of medication. Comparisons were performed with Chi-square tests.
Results:
All 176 patients were initially treated with PHT. No breakthrough clinical seizures occurred. In 70 (39.8%) patients, PHT was replaced with LEV due to adverse events including elevation of transaminases, thrombocytopenia, unexplained fever, rash, gastrointestinal disturbance, and worsening mental status. After switching to LEV, all adverse effects resolved except gastrointestinal disturbance and worsening mental status in 4 patients. Adverse events occurred more often in patients taking PHT.
Conclusions:
In patients with SAH, LEV appears to have superior tolerability compared to PHT.
Related Concept Videos
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Hemorrhagic Stroke l: Introduction
Hemorrhagic Stroke ll: Pathophysiology
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
